Acute-on-Chronic Liver Failure (ACLF)
Clinical Trial Phase I/IIa
Acute-on-chronic liver failure (ACLF) is a condition characterized by an acute hepatic decompensation in patients with chronic liver disease, which is accompanied by multiple organ failure and a profound systemic inflammatory response (Arroyo et al., 2015). Non-manageable organ damages and secondary infections account for a poor short-term survival with 30-day lethality rates ranging up to 77 %, depending on the number of extrahepatic organ failures (Baiaj et al., 2014). ACLF requires intensive care. However, in a majority of cases liver transplantation would be the only effective treatment option but is restricted by the limited availability of donor organs.
Systemic inflammation in ACLF correlates with the number of organ failures (Arroyo et al., 2015) and can therefore be considered as a significant prognostic factor. Based on their anti-inflammatory properties, ABCB5-positive (ABCB5+) mesenchymal stem cells (MSCs) could decrease systemic inflammation and thus improve the outcome in ACLF patients. Furthermore, ABCB5+ MSCs have been shown to secrete several cytokines in vitro that could attenuate liver inflammation and promote liver regeneration (Tietze et al., 2018).
The necessary safety studies for systemic (intravenous) treatment with ABCB5+ MSCs have been successfully completed.
HERE you can find more information about the clinical study using allogeneic ABCB5+ MSCs in patients with ACLF.